GlucoTrack (NASDAQ:GCTK – Get Free Report) and Exagen (NASDAQ:XGN – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.
Profitability
This table compares GlucoTrack and Exagen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GlucoTrack | N/A | -2,311.96% | -264.11% |
| Exagen | -29.97% | -105.03% | -30.10% |
Analyst Ratings
This is a breakdown of recent ratings and price targets for GlucoTrack and Exagen, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GlucoTrack | 1 | 0 | 0 | 0 | 1.00 |
| Exagen | 1 | 0 | 9 | 0 | 2.80 |
Earnings and Valuation
This table compares GlucoTrack and Exagen”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GlucoTrack | N/A | N/A | -$22.60 million | ($34.62) | -0.03 |
| Exagen | $66.57 million | 0.97 | -$19.95 million | ($0.92) | -2.91 |
Exagen has higher revenue and earnings than GlucoTrack. Exagen is trading at a lower price-to-earnings ratio than GlucoTrack, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
GlucoTrack has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500.
Institutional and Insider Ownership
10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 2.2% of GlucoTrack shares are owned by company insiders. Comparatively, 12.6% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Exagen beats GlucoTrack on 11 of the 13 factors compared between the two stocks.
About GlucoTrack
GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
About Exagen
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Receive News & Ratings for GlucoTrack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlucoTrack and related companies with MarketBeat.com's FREE daily email newsletter.
